{"id":5939,"date":"2018-07-31T08:32:02","date_gmt":"2018-07-31T07:32:02","guid":{"rendered":"http:\/\/161.116.26.48\/?p=5939"},"modified":"2018-08-27T08:34:43","modified_gmt":"2018-08-27T07:34:43","slug":"the-fourth-edition-of-science-partners-brings-together-researchers-and-investors","status":"publish","type":"post","link":"https:\/\/www.fbg.ub.edu\/en\/news\/the-fourth-edition-of-science-partners-brings-together-researchers-and-investors\/","title":{"rendered":"The fourth edition of Science + Partners brings together researchers and investors"},"content":{"rendered":"<p>On 23 July, the Bosch i Gimpera Foundation hosted the fourth edition of the Science + Partners event, which brought together specialists from the business world and researchers who carry out projects in the field of health sciences. For thirty-five minutes, researchers presented their innovations and received questions and comments from investors. \u201cScience + Partners is a very good initiative of the FBG, as it offers a first overview of early-stage projects clearly intended to be transferred by top-level researchers,\u201d remarked Laura Rodr\u00edguez, from the venture capital company Healthequity SCR, after her first participation in the event.<\/p>\n<p>The event focused on four projects of the University of Barcelona: \u201cNew HRI Activator for the treatment of type 2 diabetes and associated metabolic diseases,\u201d led by Dr. <a href=\"http:\/\/www.fbg.ub.edu\/en\/news\/manuel-vazquez-this-drug-could-treat-fatty-liver-and-insulin-resistance\/\" target=\"_blank\" rel=\"noopener\">Manel V\u00e1zquez<\/a>; \u201cAlzheimer\u2019s disease: new target and compounds,\u201d led by Dr. <a href=\"http:\/\/www.fbg.ub.edu\/en\/news\/carmen-escolano-we-have-candidate-compound-that-improves-behaviour-and-cognitive-deficit-in-two-animal-models\/\" target=\"_blank\" rel=\"noopener\">Carmen Escolano<\/a>; \u201cPediatric formulation for the treatment of tuberculosis,\u201d led by Dr. <a href=\"http:\/\/www.fbg.ub.edu\/en\/news\/josep-ma-sune-many-of-the-prescription-drugs-people-take-have-been-formulated-by-us\/\" target=\"_blank\" rel=\"noopener\">Josep Maria Su\u00f1\u00e9<\/a>; and \u201cHybris: facing organ rejection and autoimmune diseases,\u201d led by Dr. Josep Maria Gri\u00f1\u00f3. In the opinion of the partner Josep Llu\u00eds Falc\u00f3, this was the best edition of the Science + Partners he has attended so far, as \u201cthe projects were very diverse and had very high quality.\u201d<\/p>\n<p>The invited partners formed a diverse committee of industry experts, including Isabel Amat, Head of Pipeline Innovation and Management at Reig Jofre; Clara Camp\u00e0s, partner and co-founder of ASABYS Partners; Josep Llu\u00eds Falc\u00f3, CEO and founder of Genesis Biomed; Andr\u00e9s G. Fern\u00e1ndez, director of Ferrer Advanced Biotherapeutics; Laura Rodr\u00edguez, investment analyst at Healthequity SCR; Sylvain Sachot, associate investor at Ysios Capital; and Giacomo de Simone, life sciences investment analyst at Caixa Capital Risc. \u201cEvery year we witness a strengthening of the local ecosystem. This year we have seen world-class academic projects in the biopharmaceutical sector. All the ingredients are being put together for the life sciences industry to be transformative for the future of Barcelona,\u201d concluded Ysios Capital investor Sylvain Sachot.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 23 July, the Bosch i Gimpera Foundation hosted the fourth edition of the Science + Partners event, which brought&#8230;<\/p>\n","protected":false},"author":2,"featured_media":5930,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-5939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/posts\/5939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=5939"}],"version-history":[{"count":2,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/posts\/5939\/revisions"}],"predecessor-version":[{"id":5941,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/posts\/5939\/revisions\/5941"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/media\/5930"}],"wp:attachment":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=5939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=5939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=5939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}